Furthermore, expression of BRAT1 is higher in grade 4 gliomas compared to lower-grade gliomas and positively correlated with decreased overall patient survival not only in glioma, but also in renal and liver cancer, identifying BRAT1 as a putative new target for cancer treatment (https://www.proteinatlas.org/ENSG00000106009-BRAT1/pathology). Here, BRAT1 is linked to central nervous system cancer.